Dividends: October 2021

Loading...
Symbol Company Amount Yield%
ABBV AbbVie Inc 5.2 5 %
ABT Abbott Laboratories 1.8 1 %
BKE The Buckle, Inc 1.32 3 %
GHC Graham Holdings Company 6.04 1 %
IEX IDEX Corporation 2.16 1 %
MEI Methode Electronics, Inc 0.56 1 %
MGRC McGrath RentCorp 1.74 2 %
NWFL Norwood Financial Corp 1.04 4 %
TRN Trinity Industries, Inc 0.84 3 %
Symbol Company Amount Yield%
Symbol Company Amount Yield%
ADC Agree Realty Corporation 2.6 4 %
BHE Benchmark Electronics, Inc 0.66 2 %
CW Curtiss-Wright Corporation 0.72 1 %
N/A

ABBV

AbbVie Inc


--

-- As of: -- EDT

--

Open

--

Prev Close
Fundamentals
52 Wk Height
52 Wk Low
PE Ratio
Exchange: NYSE
Analyst Ratings
Strong Buy 9
Buy 1
Hold 3
Sell 0
Strong Sell 0
Stock Price Target
High $127.00
Low $97.00
Average $112.05
No. of Analysts: 20
Expected EPS

$0.00

Join Webcast
Company URL http://www.abbvie.com
Call Date -
Call Time EST
Call Pass Code ---
Call Phone No. ---
Expected EPS $0.00
Amount

$5.2

Yields

5%

Company URL http://www.abbvie.com
Declaration Date September-10-2021
Ex-Dividend Date October-14-2021
Record Date October-15-2021
Pay Date November-15-2021

Company Description:

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Sector:

Healthcare

Industry:

Drug Manufacturers—General

Social Sentiment

  • 0 Bullish
  • 0 Bearish

StockPods Mobile

Mobile Device Detected

Stockpods mobile app is on the way. Bringing the functionality of Stockpods.com to your fingertips.

For now, please enjoy our offering on a desktop or laptop.

Subscribe for the latest updated, news and features.

contact@stockpods.com

Kirkland, WA USA